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Review
A number of relevant polymorphisms are known for affecting the most common prescribed ARVs (antiretroviral), inducing
drug toxicity, risk of virologic failure and may explain the interpatient variability for drug absorption pathways. CYP3A5 is
an isoform of Cytochromes P4503A family, estimated to participate in the metabolism of 40 to 60% of all clinically
administered drugs, namely atazanavir (1). The aim of this study was to characterize the CYP3A5 polymorphisms of HIV-
infected patients, from Santa Maria Hospital, Lisbon, Portugal.
Objectives
The aim of this study was to characterize the Cyp3A5
polymorphisms of HIV-infected patients, from Santa Maria
Hospital, Lisbon, Portugal.
Single-Nucleotide Polymorphism Analysis
2 SNP (single nucleotide polymorphism) with pharmacogenetics
relevance, located at CYP3A5 gene, were genotyped by
Microarray analysis: CYP3A5, A6986G, rs776746 and CYP3A5,
27131_27132, inst rs71303343.
Experimental Methods
Results
• The SNP Hardy-Weinberg equilibrium (HWE) (p-value ≥ 0.05): 
rs776746 and rs41303343 p-value <0.0001, (table 1).
• Allelic frequencies for mutated alleles were:  rs776746 82.6% 
and rs41303343 1.96%, (table1).
• Genotype frequencies by gender and per race were statically 
significant (p-value ≥ 0.05),(table 2 and 3).
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Acknowledgements
This work was suported with Project INTELEGEN PTDC/DTP-FTO/1747/2012from Fundação para a Ciência e Tecnologia, Lisbon, 
Portugal. 
1ml blood of 27 
patients infected 
with HIV1 or co-
infected with 
HBV/C
Sample
PerfectPure DNA 
Blood Kit (5Prime)
Extraction DNA
• TaqMan® 
Genotyping
Assays
• OpenArray®
Technology
Microarray
Hardy-Weinberg 
R package based 
on χ2 – test
Statistic Analysis
SNP ID Gene Assay ID Alleles tested n Samples tested
rs776746 CYP3A5 C__26201809_30 C/T 332
rs41303343 CYP3A5 C__32287188_10 A/DEL 348
Population Characteristics
Table:1 Genotype and allele frequencies of the analysed polymorphisms
Is composed of 367 individuals infected with HIV-1 receiving ARV
therapy. In terms of gender, 253 are male and 114 are female. In
relation to the race are 275 Caucasian, 114 African and 38
unknown.
Table:2 Allele and genotype frequencies and percentage per race for CYP3A5
Table 3: Frequencies and percentage per gender for CYP3A5 
With the profile obtained by genetic characterization, performed in this study, we can conclude that the genotype frequencies for both
SNP are not the same among the groups caucasian and african.
CYP3A5*3 (rs776746) is the most common non-functional allele of the gene (2), and seems to be an import contributor to individual and
inter rational variation in CYP3A5 mediated metabolism of drugs. The CYP3A5*3 (rs776746) results evidenced more heterogeneity in
the population,, according to the literature.
Our study revealed a significant frequency of risk alleles, CYP3A5*3 and CYP3A5*7, associated with drug efficacy, safety and
recommend dosage. Therefore, could provide clinical useful information on ARV in HIV Portuguese population.
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Gene/SNP ID  N  Genotype n  Freq.(%)  95% CI  P-value
CYP3A5 332 -/- 321 96.69 (94,98.3) <0.0001* (cc)
rs41303343 -/T 9 2.71 (1.3,5.3)
T/T 2 0.60 (0.1,2.4)
- 651 98.04 (96.6,98.9)
T 13 1.96 (1.1,3.4)
CYP3A5 354 AA 28 7.91 (5.4,11.4) <0.0001*
rs776746 AG 67 18.93 (15.1,23.5)
GG 259 73.16 (68.2,77.7)
A 123 17.37 (14.7,20.4)
G 585 82.63 (79.6,85.3)
Gene/SNP ID  Allele Caucasian (%) Negroid    (%)  P-value
CYP3A5 - 458 83.58 78 14.23 <0.0001 (a)*
rs41303343 T 2 0.36 10 1.82
CYP3A5 A 41 7.04 62 10.65 0*
rs776746 G 449 77.15 30 5.15
Gene/SNP  Genotype/Alelle Male  (%) Female (%) P-value
CYP3A5 -/- 206 67.1 91 29.64 0.233 (a)
rs41303343 -/T 3 0.98 5 1.63
T/T 1 0.33 1 0.33
- 415 67.6 187 30.5 0.059
T 5 0.8 7 1.1
CYP3A5 AA 10 3.08 14 4.31 0.007
rs776746 AG 47 14.46 15 4.62
GG 168 51.69 71 21.85
A 67 43 0.049*
G 383 157
cc – Continuity correction; * significative at 5% level
(a) p-value computed via monte carlo simulation; * significative at 5% level
(a) p-value computed via monte carlo simulation; * significative at 5% level
